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Background: Patients with chronic myeloproliferative neoplasms (MPNs), including essen-
tial thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are
at high risk of vascular complications. However, the magnitude of this is risk not well known
and the possible effect of comorbidity is poorly understood.
Aim: Our aim was to compare the risk of vascular diseases in patients with MPNs and
matched comparisons from the general population and to study the effect modification of
comorbidity.
Methods: We followed 3087 patients with ET, 6076 with PV, 3719 with PMF or unspecified
MPN, and age- and sex-matched general population comparisons to estimate the risks of
cardiovascular diseases such as myocardial infarction and stroke. We computed 5-year cumula-
tive incidences (risks) for vascular disease in patients with MPNs and comparisons as well as 1-
year and 5-year risks, risk differences, and hazard ratios (HRs) for vascular diseases comparing
rates in each group of patients with their comparison cohort by level of comorbidity based on the
Charlson Comorbidity Index (CCI) [score of 0 (low comorbidity), of 1–2 (moderate comorbid-
ity), and of >2 (severe comorbidity)], as well as other comorbid conditions.
Results: The overall 5-year risk of vascular disease ranged from 0.5% to 7.7% in patients
with MPNs, which was higher than the risk in the general population. In the same period, the
adjusted HRs for vascular disease were 1.3 to 3.7 folds higher in patients with MPNs
compared to the general population. An increase in CCI score was associated with an equally
increased rate of most types of vascular diseases during the first 5 years of follow-up in both
MPN and comparisons.
Conclusion: Patients with MPNs have a higher risk of vascular diseases during the first 5
years than that of the general population; however, comorbidity modifies the rates similarly
in MPN and in the general population.
Keywords: myeloproliferative neoplasms, thrombosis, comorbidity, stroke, epidemiology
Introduction
Chronic myeloproliferative neoplasms (MPNs), encompassing essential thrombo-
cythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are
hematological cancers characterized by clonal proliferation of one or more myeloid
cell lineages in the bone marrow.1
Increased rate of vascular complications among patients with MPNs has been
recognized for decades,2 and recommendations for the management of patients are
among others based upon the assessment of the risk of vascular complications.3–5 The
criteria for high risk in PV include age above 60 and a previous thrombosis.6 Whereas
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in ET high risks of thrombosis are currently defined as having
an IPSET score ≥3 based on previous thrombosis, age above
60, presence of JAK2V617Fmutation, and also cardiovascu-
lar risk factors such as hypertension, smoking history, etc.6
Although established cardiovascular risk factors (CRFs) like
hypertension, hypercholesterolemia, and diabetes occur in
42–46%, 18–21%, and 9% of patients with PV,7,8 they have
not been found to impart a consistently increased risk of
vascular complications for patients with MPN.8–10 Even
with current medical management, survival among patients
with MPNs is lower than in the general population7,11 with
cardiovascular and cerebrovascular disorders being the lead-
ing causes of death in up to 45% of fatalities.12,13 It is there-
fore recommended that both risk factors for vascular
complications associated with MPNs such as elevated hema-
tocrit and leukocyte counts and other potential CRFs are
considered in the management of these patients.2,6,8,13–15
Despite that vascular diseases in patients with MPNs
have been long recognized, only one study has reported on
the magnitude of this rate compared to the rate of vascular
disease in the general population,16 and without including
prevalent comorbidity or cardiovascular risk factors in
analyses.
In this study, we, therefore, examined the risk of vas-
cular disease in patients with ET, PV, MF, and unspecified
MPN (MPN-U) compared to the risk in matched compar-
isons from the general population at different levels of
comorbidity.
Materials And Methods
Data Sources
The Civil Registration System (CRS) and the Danish
National Patient Registry (DNPR) provided data for this
cohort study.17,18 Since 1968, all residents in Denmark
have received a unique civil registration number (CRN)
from the CRS, allowing unambiguous individual-level
linkage between all Danish registries.17 The CRS records
the date of birth, sex, date of emigration, date of death, and
vital status of all Danish residents (8.3 million during the
study period) and it is continuously updated.
The DNPR contains information on all in-patient dis-
charges from Danish public hospitals since 1977 and on
outpatient specialist clinic and emergency room visits since
1995.18 Denmark has very few private hospitals and none are
engaged in caring for patients with hematological cancer.19
Data recorded in the DNPR include the CRN, dates of out-
patient specialist clinic visits, hospital admission and
discharge dates, as well as up to 20 diagnoses coded by
physicians according to the World Health Organisation’s
International Classification of Diseases, Eighth Revision
(ICD-8) during 1977–1993 and Tenth Revision (ICD-10),
thereafter. The primary diagnosis in the DNPR is the most
important condition treated during a given hospital contact
and represents the main reason for this contact. Secondary
diagnoses include other conditions that the physician con-
siders important to a patient's disease and treatment.18
MPN Cohorts
We identified all patients with a first MPN diagnosis by
means of ICD-8 or ICD-10 diagnosis codes recorded in the
DNPR between 1 January 1980 and 30 November 2013.
Based on the type of MPN diagnosis from 1980 and
onwards, we created three cohorts: 1) an ET patient
cohort, 2) a PV patient cohort, and 3) an MF/MPN-U
patient cohort. The MF and MPN-U diagnoses were com-
bined since patients with primary MF are likely to be
assigned an MPN-U diagnosis until the diagnostic work-
up is complete. Diagnoses of hematological malignancies
in the DNPR have been reported to be valid.20 Patients
who were assigned a single MPN diagnosis within the first
30 days after their first MPN diagnosis or patients who
were subsequently assigned only an erythrocytosis diag-
nosis code were not included in the study. The index date
was defined by adding 30 days to the first MPN diagnosis,
in order to avoid conditioning on future events and also to
define co-incident outcomes accurately. All ICD-8 and
ICD-10 codes used in this study are presented in the
Appendix, Supplementary Table 1.
Matched Population Comparison
Cohorts
Using the CRS, each patient with MPN was matched with
10 persons from the general population by sex and year of
birth in 1-year intervals. They were assigned an index date
identical to their matched patient’s diagnosis date (MPN
diagnosis date plus 30 days). Members of the comparison
cohorts had to be free of an MPN diagnosis before the
index date.21
Vascular Outcomes And Follow-Up
We used the DNPR to identify all defined cardiovascular
events in each of the three MPN and comparison cohorts.
These included acute myocardial infarction (MI), stroke,
peripheral arterial disease in the lower extremities (PAD),
Frederiksen et al Dovepress
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venous thromboembolism (VTE) [deep venous thrombosis
(DVT) in lower extremities and/or pulmonary embolism],
and splanchnic venous thrombosis (SVT). ICD codes
for these outcomes are provided in the Appendix,
Supplementary Table 1.
Vascular diagnoses have been shown to be valid in the
DNPR.22,23 Among stroke diagnoses, the highest validity
has been documented for ischemic stroke.22 We therefore
also analyzed ischemic stroke as a separate outcome. DVT
diagnoses made solely in emergency rooms (ERs) have
been suggested to be less reliable.24 For this reason, we
excluded any diagnosis made solely in the ER.
We examined multiple vascular diseases with different
pathophysiology, and therefore a vascular disease prior to
MPN diagnosis or the index date did not lead to study
exclusion. Thus, members of the patient and comparison
cohorts who had a vascular disease prior to the index date
were included in the study for follow-up of new events.
However, a vascular disease may lead to a diagnosis of
MPN, which could inflate the observed risks of vascular
diseases in these patients. We therefore also performed
sensitivity analyses restricted to patients and comparisons
who had not previously been diagnosed with any vascular
disease. Vascular diseases occurring prior to the index date
were considered as prevalent or co-incident. In adjusted
analyses, such events were included as covariates. Follow-
up started at the index date and continued until recording
of a defined vascular disease, death, emigration, or 30
November 2013, whichever came first. Patients and com-
parisons who developed one type of vascular disease con-
tinued to be followed up for other types.
Comorbidity
We computed the Charlson Comorbidity Index (CCI) score
to study the effect modification of comorbidity on risks of
vascular events in patients with MPN and members of the
comparison cohort.25 The CCI score is a weighted index,
summarizing both the number and seriousness of 19
chronic conditions. When computing CCI scores we
excluded conditions in the CCI that were also an outcome
of interest in our study. We also excluded the CCI leuke-
mia category because it includes diagnosis codes that may
overlap with MPN diagnoses. The CCI includes several
vascular diagnoses in its disease categories and CCI cal-
culations in our study therefore varied with the subtype of
the vascular disease being examined. Information on CCI
conditions was obtained from the DNPR, an approach that
has been found to be valid.26 Individual CCI scores were
based on diagnoses recorded before the index date and
were grouped in three levels: CCI score of 0 (low comor-
bidity), CCI score of 1–2 (moderate comorbidity), and CCI
score of >2 (severe comorbidity). We also used the DNPR
to calculate the number of specified CRFs including hos-
pital-based diagnoses of hypertension, obesity, hyperlipi-
demia, atrial fibrillation, and renal failure (Appendix,
Supplementary Table 1).
Sensitivity Analyses
Because blood test results of heavy smokers can resemble
those of patients with MPN, diagnostic misclassification
could occur if heavy smokers were erroneously given an
MPN diagnosis code. Thus, in order to examine the possible
effect of diagnostic misclassification of ET, PV, and MF/
MPN-U, we stratified analyses according to whether a diag-
nosis of COPD had been made before or concurrently with
the MPN diagnosis (Appendix, Supplementary Table 1).
Since we lacked direct information on smoking status,
recording of chronic obstructive pulmonary disease
(COPD) in the DNPR was used as an indicator of heavy
smoking. We used the same approach to define diagnoses
associated with alcohol overuse (Appendix, Supplementary
Table 1), allowing us to study the effects of these diagnoses
on risks of vascular diseases.
Statistical Analysis
We first computed frequency tables including sex, age,
year of index date, former vascular episodes, and CCI
conditions for patients and comparisons. We then used
the cumulative incidence function to depict risks of vas-
cular events treating death as a competing risk.27 We
computed the risk during the first year and the following
1–5 years, and 0–5 years with 95% confidence intervals
(CIs) per 100 persons for patients with MPN and mem-
bers of the comparison cohorts, as well as risk differ-
ences. Finally, we also computed incidence rates for
vascular disease per 1,000 person-years in patients and
comparisons.
Cox proportional hazard regression was used to com-
pute hazard ratios (HRs) as a measure of relative risk for
vascular events between each of the MPN cohorts and
their comparison cohorts. This analysis controlled for the
variables age, sex, and diagnosis year by study design, as
well as for comorbidity (CCI score, prevalent vascular
diagnosis, COPD, and alcohol-related diagnoses), in cal-
culating the overall risk of each of the different vascular
events (MI, stroke, PAD, VTE, and SVT). Similarly, Cox
Dovepress Frederiksen et al
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regression was used to compare rates between patients and
comparisons within each of the three MPN cohorts. The
analyses were stratified by CCI score, controlling for the
following variables: age, sex, diagnosis year, prevalent
vascular diagnosis, COPD, and alcohol-related diagnoses.
Using the same approach, we also computed absolute and
relative risks controlling for the number of predefined
CRFs. Finally, analyses were repeated after excluding
patients and matched comparisons who had experienced
a vascular event before the index date. The assumption of
proportional hazards was assessed graphically and was
potentially violated in some subgroup analyses. We, there-
fore, repeated analyses of HRs for each 1-year period of
follow-up to assess the influence of this, and HRs were
generally comparable over the time span, although some
became imprecise due to low numbers (Appendix,
Supplementary Table 7).
Ethics
This study was approved by the Danish Data Protection
Agency (record no. 1-16-02-1-08).
Results
Characteristics Of Patients And
Comparisons
During a 33-year period (1980–2013), we followed 3,087
patients with ET, 6,076 patients with PV, 3,719 patients
with MF/MPN-U, and 30,800, 60,700 and 39,530 age- and
sex-matched comparisons, respectively. The 205 ET, 177
PV, and 38 MF/MPN-U patients who died during the first
30 days after their MPN diagnosis were not included in the
study. Median follow-up ranged from 2.2 to 5.8 years in
the three cohorts, with 0.7–2.4 years in the lower quartile
and 5.0–10.5 years in the upper quartile. The median age
at diagnosis was 66 years (interquartile range (IQR) 54–76
years) for ET patients, 68 years (IQR 58–76 years) for PV
patients, and 72 years (IQR 63–80 years) for patients with
MF/MPN-U. In all MPN subtypes, the majority of patients
were diagnosed in the most recent study period, due to the
later inclusion of diagnoses conferred during outpatient
hospital contacts (Table 1).
In general, a larger proportion of patients with MPNs
had comorbidities and cardiovascular diseases prior to
index date than comparisons (Table 1). Accordingly, the
proportion of patients with moderate or severe comorbid-
ity or presence of CRFs as of the index date was consis-
tently higher in patients with MPNs, irrespective of
subtype, than in matched comparisons (Table 1). For
example, 27–33% of patients with MPN had at least one
of the defined cardiovascular risk factors compared to
14–18% in comparisons (Table 1).
Risk Of Vascular Diseases
After being diagnosed with MPN, patients with ET or PV
generally experienced higher rates of both arterial and
venous vascular diseases, than members of the comparison
cohorts (Figures 1 and 2). The general risk of vascular
disease during the first 5 years ranged from 0.5% to 7.7%
in patients with MPN. These 5-year risks were consistently
higher among patients with ET or PV than among their
comparisons with five-year increases in risk ranging from
0.6% to 4.3% points (Appendix, Supplementary Table 2).
In addition, the adjusted HRs for vascular diseases were
1.3 to 3.7 fold elevated during the first 5 years and across
the different MPN subtypes and the different vascular
diseases – e.g., the adjusted HR for stroke in patients
with ET vs comparisons was 1.6 (95% CI 1.4–1.9)
(Appendix, Supplementary Table 2). Similar results were
seen in patients with MF/MPN-U for VTE and PAD
(Figure 3, Appendix Supplementary Table 2). SVT, a
rare disease, was mainly observed prior to or within 30
days following an MPN diagnosis (Table 1, Figures 1–3).
During 1980–1989, 1990–1999, and 2000–2013 the 5-year
risks of vascular disease were much the same although the
low number of patients included during 1980–1989
resulted in imprecise risk estimates in this period
(Appendix, Supplementary Table 2). The incidence rates
of all subtypes of vascular disease were higher in patients
with MPN than in members of the comparison cohorts
during the first 5 years of follow-up (Supplementary
Table 3).
Tables 2 and 3 show the risks, risk differences, and
adjusted HRs by type of vascular disease in patients and
comparisons during the first year of follow-up and the next
two to 5 years according to the level of comorbidity. An
incremental comorbidity score was associated with
increased absolute risks of most types of vascular diseases
of the same magnitude in both patients with MPN and
members of the comparison cohorts (Tables 2 and 3). For
MI, stroke, and PAD, a stepwise increased rate of vascular
disease was observed by increasing comorbidity level in
parallel for both patients with MPN and matched compar-
isons (Tables 2 and 3). Generally, the increased risk of
vascular diseases, from the first year to the following 1–5
years, and the adjusted HRs were similar among patients
Frederiksen et al Dovepress
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Table 1 Characteristics And Comorbidity Of Patients With Essential Thrombocythemia (ET), Polycythemia Vera (PV), And
Myelofibrosis/Unclassified Myeloproliferative Neoplasm (MF/MPN-U), And Members Of The Age- And Sex-Matched General
Population Comparison Cohort. Figures Are Counts (N) And Proportions In Percent With The Characteristic
ET Cohort ET
Comparison
Cohort
PV Cohort PV
Comparison
Cohort
MF/MPN-
U
MF/MPN-U
Comparison
Cohort
n % n % n % n % n % n %
Sex 3087 100 30,870 100 6076 100 60,760 100 3719 100 37,190 100
Women 1990 64.5 19,900 64.5 2774 45.7 27,740 45.7 1886 49.3 18,860 49.3
Men 1097 35.5 10,970 35.5 3302 54.3 33,020 54.3 1833 50.7 18,330 50.7
Age group
20–49 years 584 19.0 5840 19.0 761 12.5 7610 12.5 293 7.9 2930 7.9
50–69 years 1199 38.9 11,990 38.9 2603 42.8 26,030 42.8 1219 32.8 12,190 32.8
70+ years 1304 42.2 13,040 42.2 2712 44.6 27,120 44.6 2207 59.3 22,070 59.3
Year of MPN diagnosis/index year
1980–1989 33 1.1 330 1.1 1827 30.1 18,270 30.1 680 18.3 6800 18.3
1990–1999 716 23.2 7160 23.2 1863 30.7 18,630 30.7 1025 27.6 10,250 29.6
2000–2013 2338 75.7 23,380 75.7 2386 39.2 23,860 39.2 2014 54.1 20,140 54.1
Morbidity at MPN diagnosis/index date*
Myocardial infarction 197 6.4 1138 3.7 442 7.3 2321 3.8 235 6.3 1891 5.1
Congestive heart failure 153 5.0 955 3.1 472 7.8 1692 2.8 272 7.3 1454 3.9
Atrial fibrillation 192 3.7 1443 4.7 468 7.7 2064 3.4 298 8.0 1886 5.1
Peripheral vascular disease 302 9.8 1003 3.2 526 8.7 1659 2.7 339 9.1 1286 3.5
Cerebrovascular disease 450 14.6 1969 6.4 1005 16.5 3376 5.6 438 11.8 2815 7.6
Dementia 48 1.6 347 1.1 59 1.0 527 0.9 339 9.1 2253 6.1
Chronic pulmonary disease 297 9.6 1969 6.4 679 11.2 2779 4.6 81 8.9 432 3.7
Connective tissue disease 134 4.3 817 2.6 158 2.6 1159 1.9 205 5.5 952 2.6
Ulcer disease 200 6.5 1015 3.3 352 5.8 1935 3.2 287 7.7 1476 4.0
Mild liver disease 51 1.7 223 0.7 88 1.4 326 0.5 57 1.5 208 0.6
Moderate to severe liver disease 18 0.6 59 0.2 29 0.5 77 0.1 15 0.4 55 0.1
Hemiplegia 8 0.3 56 0.2 26 0.4 112 0.2 10 0.3 67 0.2
Diabetes type I or II 173 5.6 1159 3.8 388 6.4 2047 3.4 234 6.3 1605 4.3
Diabetes with end-organ damage 85 2.8 483 1.6 117 1.9 766 1.3 19 1.6 81 0.7
Obesity 114 3.7 776 2.5 245 4.0 1058 1.7 106 2.9 792 2.1
Moderate to severe renal disease 67 2.2 349 1.1 100 1.6 419 0.7 119 3.2 444 1.2
Hyperlipidemia 144 4.7 837 2.2 177 2.9 1013 1.7 125 3.4 959 2.6
Hypertension 573 18.6 3269 10.6 1218 20.0 4604 7.6 563 15.1 3883 10.4
Any tumour (except basal cell carcinoma) 289 9.4 2522 8.2 474 7.8 3911 6.4 449 12.1 3270 8.8
Lymphoma 26 0.8 122 0.4 31 0.5 169 0.3 93 2.5 127 0.3
Metastatic solid tumour 24 0.8 184 0.6 43 0.7 288 0.5 37 1.0 235 0.6
AIDS <3 9 <3 <3 <3 <3
Charlson comorbidity index score*
Low comorbidity (0) 1637 53.0 22,178 71.8 3081 50.7 46,075 75.8 1868 50.2 25,599 68.8
Moderate (1–2) 1104 35.8 6861 22.2 2402 39.5 11,936 19.6 1374 36.9 9262 24.9
High (>2) 346 11.2 1831 5.9 593 9.8 2749 4.5 444 12.8 2329 6.3
Number of known cardiovascular risk factors
#, *
0 2194 71.1 25,305 82.0 4156 68.4 52,419 86.3 2693 72.4 30,381 81.7
1 609 19.7 3768 12.2 1370 22.5 5950 9.8 692 18.6 4655 12.5
2 208 6.7 1332 4.3 419 6.9 1794 3.0 255 6.9 1594 4.3
(Continued)
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with MPN and comparisons (Tables 2 and 3) and also
between the three MPN subtypes the risks of each type
of vascular disease and HRs were generally similar
(Appendix, Supplementary Table 2, and Tables 2 and 3).
Sensitivity Analyses
Five-year cumulative risks for cardiovascular diseases
stratified by presence vs absence of a previous COPD
diagnosis are presented in Supplementary Table 4. The
Table 1 (Continued).
ET Cohort ET
Comparison
Cohort
PV Cohort PV
Comparison
Cohort
MF/MPN-
U
MF/MPN-U
Comparison
Cohort
n % n % n % n % n % n %
≥ 3 76 2.5 465 1.5 131 2.2 597 1.0 79 2.1 560 1.5
Chronic obstructive pulmonary disease* 244 7.9 1364 4.4 595 9.8 2241 3.7 286 7.7 1870 5.0
Alcohol-related diagnosis* 165 5.3 781 2.5 254 4.2 1224 2.0 147 4.0 776 2.1
Previous myocardial infarction* 198 6.4 1143 3.7 454 7.5 2337 3.8 241 6.5 1901 5.1
Previous stroke* 286 9.3 1171 3.8 565 9.3 1809 3.0 251 6.7 1597 4.3
Previous peripheral arterial disease, lower
extremity
196 6.3 545 1.8 336 5.5 899 1.5 202 5.4 687 1.8
Previous venous thromboembolism* 130 4.2 573 1.9 395 6.5 965 1.6 194 5.2 735 2.0
Previous splanchnic thrombosis* 21 0.7 <3 30 0.5 5 0.0 17 0.5 4 0.0
Notes: *All diagnoses registered before and up to 30 days after an MPN diagnosis or index date for members of the comparison cohorts. #Hypertension, diabetes, obesity,
hyperlipidemia, atrial fibrillation, or renal failure.
Figure 1 Cumulative incidences of vascular events in patients with essential thrombocythemia (ET) and age- and sex-matchedmembers of general population comparison cohorts.
Abbreviations: MI, myocardial infarction; PAD, peripheral arterial disease lower extremity; VTE, venous thromboembolism; SVT, splanchnic venous thrombosis.
Frederiksen et al Dovepress
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risks were elevated in all MPN subgroups, with no clear
differences attributable to the COPD diagnosis.
In the Supplementary Table 5 risks of vascular diseases
are shown by the number of specified CRFs and these
results are almost identical to those of the subgroups
defined by CCI score. Finally, analyses restricted to
patients and comparisons without a previous vascular
diagnosis lowered the 5-year risks among patients, leading
to lower risk differences between patients with MPN and
their matched comparisons (Supplementary Table 6).
Discussion
Our results showed that 5-year risks of arterial or venous
vascular disease ranged from 0.5% to 7.7% for patients
with MPN and were elevated compared to the general
population with adjusted HRs ranging from 1.3 to 3.7. In
most groups, increased comorbidity was associated with a
similarly increased risk of vascular disease among patients
with MPN and among their comparisons during the first 5
years.
Some features of our study may have affected the
observed risks of vascular disease. First, patients with
MPN were identified using population-based registries
with complete follow-up.10,13 Patients with MPN without
a hospital admission could not be identified in DNPR
before 1995. Therefore, patients from this period with
more severe MPN disease, possibly also with a higher
risk of vascular complications, could have been selected
disproportionately. We did, however, not detect the effects
of this shortcoming since risks of vascular events in
patients were much the same across different time periods.
In the MF/MPN-U subtype, some of the cumulative inci-
dence curves cross after 5–15 years of follow-up
(Figure 3); this probably reflects a survivorship bias, i.e.,
that in this group with high early mortality the patients
who remain alive at a given time are selected for good
health.28
Patients with MPN were identified using ICD diagnosis
codes which could have led to diagnostic misclassification,
for instance, if patients with secondary polycythemia were
erroneously given a PV diagnosis code. Although we
cannot rule out that this constraint influenced our results,
our stratified analyses indicated that risks of vascular
events were nearly the same for patients with and without
Figure 2 Cumulative incidences of vascular events in patients with polycythemia vera (PV) and age- and sex-matched members of general population comparison cohorts.
Abbreviations: MI, myocardial infarction; PAD, peripheral arterial disease lower extremity; VTE, venous thromboembolism; SVT, splanchnic venous thrombosis.
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COPD. As well, in a previous study with almost identi-
cally defined patients, we demonstrated that ET and PV
patients had the expected later occurrence of hematologi-
cal transformation.29
Another concern is that we defined the MPN subtype
based on the first MPN diagnosis code. It is well known
that the specific MPN subtype may not always be deter-
mined during a first hospital visit, and that patients with
MPNs may later be assigned a different MPN subtype due
to progression or emergence of new clinical or para-clin-
ical results. Our definition probably explains the relatively
high proportion of patients with the MPN-U subtype. The
capture of the rare patients with primary MF was probably
in particular affected by the MPN subtype definition, and
our results from our aggregated MF/MPN-U group may
not reflect vascular risks in patients with primary MF
accurately.
Our registry-based data did not include detailed infor-
mation on patient-specific characteristics such as blood
pressure, smoking habits, body mass index, or molecular
or treatment-specific factors that would have allowed us to
investigate other factors that could influence thrombosis
risk among patients with MPNs. As well, our CCI calcula-
tion was based on diagnoses made in outpatient specialist
clinics and during hospital admissions. This approach may
not capture all comorbid diagnoses, such as type 2 diabetes,
hypertension, or dementia followed in general practice
without a hospital referral. However, these limitations affect
both patients and members of the comparison cohorts. Our
primary goal was to assess the risk of vascular disease
conveyed through comorbid conditions that to some extent
represent “end-stage” conditions associated with some of
the unknown risk factors for vascular disease in the causal
pathway. We also cannot rule out that patients with MPNs
were more likely to have comorbid diagnoses registered
during their hospital stay compared with members of the
general population cohort. This could have given a conser-
vative bias to our estimates of the effects of comorbidity on
the risk of vascular disease. Similarly, we include only
patients who have an inpatient recording of a vascular
disease. Due to advances in diagnosis and treatment of
DVT, this is now often managed in the out-patient setting.
Figure 3 Cumulative incidences of vascular events in patients with myelofibrosis or unclassified myeloproliferative neoplasm and age- and sex-matched comparisons from
the general population.
Abbreviations: MI, myocardial infarction; PAD, peripheral arterial disease lower extremity; VTE, venous thromboembolism; SVT, splanchnic venous thrombosis.
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Therefore, our absolute risk estimates for DVT may be
conservative – particularly in more recent time periods.
At index date, the proportion of patients with cardiovas-
cular morbidity was highest in patients with MPN. This was
observed both for cardiovascular diagnoses such as stroke,
myocardial infarction, and peripheral vascular disease and
for other risk factors such as obesity, hypertension, etc. This
skewed distribution of underlying risk factors was con-
trolled in the multivariate analysis but unmeasured and
residual confounding from unmeasured and incompletely
measured risk factors may still influence our results. When
we exclude patients with prevalent vascular diseases the
risk differences became smaller; however, the HRs for
patients vs comparisons were much the same, emphasizing
that the MPN is a risk factor in itself.
Although vascular complications of MPNs have long
been recognized, it was not until recently that a study
found that patients with MPNs identified in the Swedish
Cancer Register had a 3-month HR for arterial thrombosis
that was 3-fold elevated and 9-fold elevated for venous
thrombosis among patients with MPNs compared to age-
and sex-matched comparisons from the general
population.16 The magnitude of this relative increase was
comparable across MPN subtypes for arterial events. In
contrast, patients with PVexhibited a higher rate of venous
thromboembolic events compared to patients with other
MPNs.16 Throughout the study period, HRs for both arter-
ial and venous thromboses remained elevated. In line with
these results, 16 we found that HRs were somewhat lower
but still elevated for all types of vascular diseases.
Thrombotic risks, thrombotic deaths, or major thrombotic
events have previously been reported to occur among 2.8%
to 9.8% of 365 patients with PVafter a median follow-up of
31 months.30 In another study, the incidence of both fatal and
nonfatal thrombotic events was 1.9/100 person-years among
891 patients with ET followed for a median of 6.2 years.10 In
the latter study, the incidence of nonfatal arterial thrombotic
events was 1.2/100 person-years and that of venous events
was 0.6/100 person-years. More specifically, the incidence of
MI was 0.3/100 person-years and 0.7/100 person-years for
stroke.10 In the ECLAP trial, a cohort of 1,638 patients who
had been diagnosed with PV within the previous 0–2 years
(35.5%) or earlier was followed from inclusion at 94 hema-
tological centers across 12 countries.13 In this study, the
incidence of fatal and nonfatal thrombosis after study inclu-
sion was 5.5/100 person-years, the incidence of MI and
stroke was 0.3/100 and1.4/100 per person-years,
respectively.13 Our incidence rates of MI and stroke were
somewhat higher than these previous studies possibly reflect-
ing both the complete follow-up in our cohort and inclusion
of patients from the time of MPN diagnosis. In a previous
study, some patients have already received treatment for
MPN before inclusion.13 The proportion of patients in our
study who suffered an SVT before or after MPN diagnosis
was approximately 0.5–1%. This proportion is considerably
lower than another observational study from the Mayo clinic
were 53/587 (9.4%) of patients with PV suffered this rare
complication.8 The discrepancy probably reflects that the risk
profile in patients from tertiary referral centers may not be
comparable to the general MPN patients.
Pathophysiology of vascular complications in patients
with MPN is complex involving multiple factors such as
inflammation, age, high blood counts, cardiovascular risk
factors, but also MPN driver mutations may directly or
indirectly increase risks.13,30–32 Recently, a study among
20,000 general population adults revealed that a
JAK2V617F or a CALR mutation was identified in 3.1%.33
These persons were more likely to be smokers, to have prior
thrombosis, and had higher blood counts than population.
The study emphasizes that pre-diagnostic phase inMPNmay
be long, and that some of the pre-MPN vascular events may
be preventable through screening and management of shared
risk factors.33
Conclusion
We conclude that vascular diseases and cardiovascular risk
factors are more prevalent in patients with MPNs, com-
pared to the general population, and that patients have an
1.3 to 3.7 times increased rate of a new arterial and venous
vascular diseases, depending on MPN subtype, and type of
vascular disease. The rate seems to be modified to the
same extent by comorbidity in patients with MPNs as in
the general population.
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